SarcoidosisUK is one of the worlds leading investors in research into sarcoidosis. We are committed to finding a cure.

Sarcoidosis is a rare disease and does not receive sufficient attention from pharmaceutical companies or medical researchers.

SarcoidosisUK may be small but we are a leading investor in sarcoidosis research. We have now raised sufficient money to fund a new research project for each of the next three years. With your support, SarcoidosisUK will continue fighting sarcoidosis. To ensure greater efficiency, we conduct our research in partnership with the British Lung Foundation.

SarcoidosisUK aims to fund at least one major sarcoidosis research project each year. We will continue to do this again and again until we have found a cure. We receive no government funding - this research would not be possible without your generous donations.

SarcoidosisUK-BLF Research Grant 2017

Dr Steven Fowler

Dr Steven Fowler, University of Manchester, has been awarded the 2017 SarcoidosisUK-BLF Sarcoidosis Research Grant.

Overview: Sarcoidosis is thought to be caused by the patient’s immune system overreacting to an unknown substance in the air that is breathed in. This project will analyse breath sample from sarcoidosis patients. The data will tell us more about a number of important issues relating to sarcoidosis, such as its cause, the importance of lung infection and inflammation, and whether it is responding to treatment.

Location: University of Manchester

Researcher: Dr Steven Fowler, Senior Lecturer and Honorary Consultant in Respiratory Medicine at the University of Manchester

Cost: £120,000

Start date: 2018; End date: 2021

"We are really grateful to Sarcoidosis UK and the British Lung Foundation for awarding us this prestigious grant. We are going to use it to investigate whether there we can detect chemical signals in the breath that can give us information about the severity, the presence of infection and/or inflammation, and perhaps the cause of sarcoidosis in any individual.  Whilst the analysis of these breath samples is complex, the collection procedure itself is very simple, and would offer significant advantages compared to current methods of sampling the lungs."

Dr Steven Fowler, University of Manchester

“We are thrilled to be in a position to fund Dr Fowler’s research. The prospect of being able to find out more about possible environmental causes of sarcoidosis from a simple and non-invasive breath analysis is extremely exciting for us and the patients we support. We are very much looking forward to seeing the results that will come from this investment."

Henry Shelford, SarcoidosisUK Chairperson

SarcoidosisUK-BLF Research Grant 2016

Overview: Sarcoidosis involving the heart can present severe risks of heart rhythm disturbances and even sudden death. Early detection of cardiac sarcoidosis, therefore, is critical. The SarcoidosisUK-BLF Sarcoidosis Research grant will enable a team to investigate the best non-invasive diagnostic tests to identify cardiac disease and identify potential blood-based biomarkers that could indicate cardiac disease.

Location: Papworth Hospital, Cambridge

Researcher: Dr Muhunthan Thillai, Lead Clinician & Consultant Chest Physician of Cambridge Interstitial Lung Disease Unit

Cost: £112,000

Start date: April 2017; End date: Spring 2020


Papworth Hospital Research Team: (L-R) Dr Muhunthan Thillai, Lead Clinician & Consultant Chest Physician, Dr Lynne Williams, Consultant Cardiologist, Dr Katharine Tweed, Radiologist, and Dr Sharad Agarwal, Consultant Cardiologist.

"This is an exciting collaboration between Papworth Hospital and Imperial College London. Using a sequence of cardiac tests to identify patients at risk, could transform the lives of so many sarcoidosis patients.

Additionally, the potential of using state-of-the-art protein sequencing to identify blood markers in predicting cardiac disease, could open up more opportunities for early diagnosis.”

Dr Thaillai,  Papworth Hospital 

SarcoidosisUK-BLF Research Grant 2015


A monocyte white blood cell. Dr Hart's research is investigating impairments to monocyte cells in sarcoidosis patients.

Overview: SarcoidosisUK commissioned a 2-year academic research project in partnership with the British Lung Foundation. The project is investigating protein molecules affecting monocyte (a type of white blood cell that regulates immunity against foreign substances, left) function in sarcoidosis. Studying the immune response in sarcoidosis in this way may identify targets for specific new therapies.

Location: Castle Hill Hospital, Hull York Medical School

Researcher: Dr Simon Hart, Senior Lecturer in Respiratory Medicine at the Hull York Medical School

Cost: £116,000

Start date: April 2016; End date: Spring 2018

"We are very grateful to SarcoidosisUK for funding our research which aims to understand the over-active immune response in pulmonary sarcoidosis by studying biomarkers in blood samples. We anticipate that our findings from this part [year 1] of the study will determine: 1) whether blood biomarkers are stable over time; and 2) whether blood biomarkers could be used in future studies to help predict disease progression, remission, or responsiveness to therapy."

Dr Hart, Hull York Medical School, July 2017

"We aim to show whether regulatory receptors could be used to identify, early on, whether sarcoidosis is likely to worsen or improve. By extending our knowledge of the immune dysfunction in sarcoidosis, it could pave the way for clinical trials in patients of drugs [that could provide therapeutic relief of symptoms]."

Dr Hart, Hull York Medical School, April 2016


SarcoidosisUK and the British Lung Foundation are inviting full applications for a grant to support sarcoidosis research.

The grant is available to medically qualified applicants, post-doctoral scientists or allied health professionals for clinical, laboratory and/or epidemiological research into sarcoidosis.

Grants are for a specified period of up to three years to a maximum of £120,000.

Applications may seek costs for personnel, equipment and consumables etc. where appropriate. The grant-holding institution must be based in the United Kingdom.